Assuntos
Injúria Renal Aguda/imunologia , Infecções por HIV/complicações , Nefrite Intersticial/imunologia , Púrpura Trombocitopênica Trombótica/diagnóstico , Injúria Renal Aguda/diagnóstico , Injúria Renal Aguda/terapia , Biópsia , Medula Óssea/patologia , Feminino , Infecções por HIV/imunologia , Humanos , Rim/patologia , Pessoa de Meia-Idade , Nefrite Intersticial/diagnóstico , Nefrite Intersticial/terapia , Troca Plasmática , Púrpura Trombocitopênica Trombótica/complicações , Púrpura Trombocitopênica Trombótica/terapia , Diálise Renal , Resultado do TratamentoAssuntos
Injúria Renal Aguda/induzido quimicamente , Antineoplásicos/efeitos adversos , Filgrastim/efeitos adversos , Glomerulonefrite/induzido quimicamente , Rim/efeitos dos fármacos , Linfoma de Células B/tratamento farmacológico , Polietilenoglicóis/efeitos adversos , Injúria Renal Aguda/diagnóstico , Injúria Renal Aguda/imunologia , Idoso , Biópsia , Imunofluorescência , Glomerulonefrite/diagnóstico , Glomerulonefrite/imunologia , Humanos , Rim/imunologia , Rim/ultraestrutura , Linfoma de Células B/imunologia , Linfoma de Células B/patologia , Masculino , Microscopia Eletrônica , Necrose , Gradação de Tumores , Fatores de RiscoRESUMO
BACKGROUND: Serratia is an opportunistic pathogen known to cause an array of infectious presentations. Aside from case reports, intravenous (IV) drug use has not been adequately quantified as a major risk factor for Serratia infection. METHODS: A retrospective cohort study of 103 adult patients admitted to four community hospitals in Ohio from January 2014 to December 2018 with a positive blood culture for Serratia species. A complete data set of 103 patients was analyzed for demographics, comorbidities, initial diagnosis, treatment, and outcomes. Outcomes were recurrence of infection, in hospital mortality, 90-day mortality, length of hospital stay (LOS), complications (endocarditis, osteomyelitis, abscess), and evaluation for resistance to third-generation cephalosporins and extended-spectrum beta-lactamase (ESBL) activity. Descriptive statistics were performed using frequencies for discrete variables and median [interquartile range (IQR)] for continuous variables. RESULTS: Serratia marcescens was the predominate species 94 (91%). Demographics were White 88 (85%) and male 63 (62%); 42 (42%) were IV drug users. IV drug users were younger than non-IV drug users with a median (IQR) age of 40 [33-50] versus 71 years [41-72] and likely to have hepatitis C virus (HCV) infection 37 (88%) versus 3 (5%), p < 0.0001. Culture and susceptibility analysis revealed 36% of isolates with possible or confirmed ESBL production. The most common complications were endocarditis (12%) and osteomyelitis (10%). In-hospital mortality was 2%, 90-day mortality (2%), with 90-day readmission (21%). The median (IQR) LOS is 7 [3.25-14.75]. CONCLUSION: This is the largest study to our knowledge evaluating non-nosocomial Serratia bacteremia. Our study shows that a high proportion of patients hospitalized with a positive Serratia culture are IV drug users and have HCV co-infection. There is significant ceftriaxone resistance and ESBL activity noted in our population. Based on this, we suggest empiric treatment with cefepime or consider carbapenem therapy for Serratia bloodstream isolates pending full susceptibility data. Focus should be on proper antibiotic treatment as the readmission rate and LOS are high.
RESUMO
The kidney is one of the major organs affected in preeclampsia. There is evidence suggesting a role for excessive complement activation in the pathogenesis of preeclampsia. We describe a case of preeclampsia with severe features, including HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) and acute kidney injury (AKI) that developed following caesarian section. The patient required renal replacement therapy. A trial of daily plasma exchange was not effective. The patient received a single dose of eculizumab, a humanised monoclonal IgG antibody that binds to complement protein C5. One week post administration of eculizumab, there was significant improvement in haematologic, hepatic and renal function. Blood pressure had normalised and renal replacement therapy was discontinued. The use of eculizumab may have contributed to recovery of kidney function further supporting the role of complement activation in the pathogenesis of preeclampsia and associated AKI.